Defining Optimal Immunotherapies for Type 1 Diabetes


Book Description

This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D). Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials. The book integrates information from human and animal studies. The book considers T1D within the broader context of autoimmune disease. The format contains several discussions, which address specific questions and provides guidelines for future strategies and solutions for discovering a cure.




Immunotherapy of Type 1 Diabetes


Book Description

Recent national, European and international diabetes meetings have seen controversial discussions on the potential benefit and also on ethical aspects of immune intervention in patients with Type 1 diabetes or in persons with a high risk of developing the disease.




Stem Cells – From Hype to Real Hope


Book Description

This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.




Type 1 Diabetes


Book Description

In the field of immunology, type 1 diabetes has become one of the major areas of investigation with studies that span from characterization of key molecules to trials for the prevention of the disease. Type 1 Diabetes : Molecular, Cellular and Clinical Immunology communicates both the background and the most recent understanding of this disorder, which will almost certainly be central to elucidating the etiology of autoimmunity, and in particular of organ specific autoimmunity. The book covers immunogenetics, immunopathogenesis, epidemiology, disease prediction and clinical application of current knowledge. Both scientists seeking to understand and prevent type 1 diabetes/autoimmunity as well as physicians caring for families with type 1 diabetes will be interested in this book.




Therapeutic Perspectives in Type-1 Diabetes


Book Description

This book provides critical insights into and appraisals of recent breakthroughs in type 1 diabetes modulation, with a particular emphasis on the potential impact of current prevention and treatment strategies. It also discusses recent successes and failures in clinical trials. Presenting an comprehensive overview of the disease, it is especially useful for newcomers in the field. It also includes illustrations, which make it easy for the reader to grasp the basic concepts involved. Furthermore, the tables include concise and easy-to-understand information on current clinical trials.




Medical Management of Type 1 Diabetes


Book Description

Type 1 diabetes, formerly known as juvenile diabetes, is a complex disorder that requires a great deal of patient-guided self-care. In recent years, advances in diabetes treatment have dramatically shifted potential outcomes in the favor of the patient with diabetes. The challenge for health care professionals is to realize this potential through an individualized, flexible, and responsive treatment plan for patients with type 1 diabetes. Now in its seventh edition, Medical Management of Type 1 Diabetes offers health care providers the newest information and guidelines for the treatment of type 1 diabetes. Built on the foundation of multiple daily insulin injections and insulin pump therapy, this book guides health care providers in helping their patients continually strive for optimal blood glucose control. This new edition focuses on the latest molecular advances, new treatment methods, recent clinical trials, and the American Diabetes Association's Standards of Care. Key topics also include new insulins and administration protocols, advanced carbohydrate counting, and emphasis on continuing patient education. Individual sections address all of the topics in managing type 1 diabetes, including diagnosis and classification/pathogenesis, diabetes standards and education, tools of therapy, special situations, psychosocial factors affecting adherence, quality of life, and well-being and complications. Medical Management of Type 1 Diabetes is an essential addition to any clinician's library for the treatment and understanding of type 1 diabetes.




Targeting a Cure for Type 1 Diabetes: How Long Will We Have to Wait?


Book Description

Will type 1 diabetes ever be cured? Everyone whose lives are touched by type 1 diabetes hopes for a cure but hard facts are difficult to find. Targeting a Cure for Type 1 Diabetes chronicles the diverse efforts now underway to answer this critical question. The writers from diaTribe (www.diaTribe.org), an award-winning free online newsletter about diabetes, have collaborated with the American Diabetes Association to explain the research and to lay out their objective assessment of each therapy—giving readers a clear understanding of the potential each treatment holds and the optimism each deserves. Highlighting the opportunities and obstacles, this book focuses on the four most promising research areas: immune therapeutics, islet and pancreas transplantation, beta-cell regeneration and survival agents, and the artificial pancreas. As a person who has lived with type 1 diabetes for 26 years and an expert on the business of diabetes therapies, diaTribe editor-in-chief Kelly Close understands the weight of this all-important question and provides her personal commentary on where we stand in the search for a cure. The book features a foreword by Dr. Robert Ratner, Chief Scientific and Medical Officer for the American Diabetes Association, and an introduction from Dr. Aaron Kowalski, Vice President, Treatment Therapies, for JDRF. As they remind us, the search for the cure is ultimately about patients, and this book is written to give you true hope—one that is strengthened by data and facts. After reading about Kelly Close and her teams’ incredible journey of discovery, we cannot only continue to dream, but we can open our eyes each morning to a reality that brings us closer, inch by inch, discovery by discovery, to a day when glucose control will be automatic and people with type 1 diabetes will be “cured.” —Dr. Francine Kaufman, Chief Medical Officer and Vice President, Medtronic Diabetes




Immunotherapy of Hepatocellular Carcinoma


Book Description

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.




CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential


Book Description

The vertebrate immune system defends the organism against invading pathogens while at the same time being self-tolerant to the body’s own constituents thus preserving its integrity. Multiple mechanisms work in concert to ensure self-tolerance. Apart from purging the T cell repertoire from auto-reactive T cells via negative selection in the thymus dominant tolerance exerted by regulatory T cells plays a major role in tolerance imposition and maintenance. Among the various regulatory/suppressive cells hitherto described, CD4+CD25+ regulatory T cells (Treg) and interleukin-10 producing T regulatory 1 (Tr1) cells have been studied in most detail and are the subject of most articles in this issue. Treg, also called "natural" regulatory T cells, will be traced from their intra-thymic origin to the site of their action in peripheral lymphoid organs and tissues. The repertoire of Treg is clearly biased towards recognition of self-antigens, thereby potentially preventing autoimmune diseases such as gastritis and oophoritis. Regulatory T cells, however also control infections, allergies and tolerance to transplanted tissues and this requires their induction in the periphery under conditions which are not yet fully understood. The concept of dominant tolerance, by far not novel, will offer new insights and hopefully tools for the successful treatment of autoimmune diseases, improved cancer immunotherapy and transplant survival. The fulfillment of these high expectations will, however, require their unambiguous identification and a better understanding of their mode of action.